Amyotrophic Lateral Sclerosis Clinical Trials

11 trials recruiting in Canada.

Brain & Nervous System

Recruiting Drug Device Behavioral Older adults Healthy volunteers

11 trials

Testing LY4256984 against a placebo for ALS (amyotrophic lateral sclerosis)

Explore this study →

There are 2 groups in this study. Group A receives LY4256984. Group B, the placebo group, receives Placebo.

Sites in Calgary, Edmonton and 3 more cities

Phase 1
2 groups
Sites in Calgary, Edmonton and 3 more cities
Recruiting

Official title: A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

ALS (Amyotrophic Lateral Sclerosis) · Eli Lilly and Company

Testing Pridopidine against a placebo for amyotrophic lateral sclerosis

Explore this study →

There are 2 groups in this study. Group A receives Pridopidine. Group B, the placebo group, receives Placebo.

Sites in Edmonton, Hamilton and 1 more city

Phase 3
2 groups
Sites in Montreal, Edmonton and 1 more city
Recruiting

Official title: Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Amyotrophic Lateral Sclerosis · Prilenia

Testing Darifenacin against a placebo for amyotrophic lateral sclerosis

Explore this study →

There are 2 groups in this study. Group A receives Darifenacin 7.5 MG Extended Release Oral Tablet. Group B, the placebo group, receives Placebo.

Sites in Montreal and Ottawa

Phase 2
2 groups
Sites in Ottawa and Montreal
Recruiting

Official title: A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Amyotrophic Lateral Sclerosis · Oliver Blanchard

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for amyotrophic lateral sclerosis.

Testing LY4256984 for amyotrophic lateral sclerosis

Explore this study →

Everyone in this study is in one group and receives LY4256984.

Sites in Calgary, London and 2 more cities

Phase 1
1 group
Sites in Calgary, London and 2 more cities
Recruiting

Official title: A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis · Eli Lilly and Company

Testing LY4256984 for amyotrophic lateral sclerosis

Explore this study →

Everyone in this study is in one group and receives LY4256984.

Sites in Calgary, London and 2 more cities

Phase 1
1 group
Sites in Calgary, London and 2 more cities
Recruiting

Official title: A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis · Eli Lilly and Company

Testing NB-4746 High dose against a placebo for amyotrophic lateral sclerosis (ALS)

Explore this study →

There are 5 groups in this study. Group A receives NB-4746 High dose. Group B receives NB-4746 Low dose. Groups C and E, the placebo group, receive Placebo. …and 1 more groups.

Sites in Fredericton, Montreal and 1 more city

Phase 1
5 groups
Sites in Fredericton, Toronto and 1 more city
Recruiting

Official title: A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

Amyotrophic Lateral Sclerosis (ALS) · Nura Bio

Comparing 6 approaches for amyotrophic lateral sclerosis (ALS)

Explore this study →

There are 6 groups in this study. Groups A, B, C, D and E receive one or more of: ALN-SOD, Diluent and Placebo (PB). Group F receives ALN-SOD.

Sites in Edmonton, London and 2 more cities

Phase 1
6 groups
Sites in Edmonton, London and 2 more cities
Recruiting

Official title: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Amyotrophic Lateral Sclerosis (ALS) · Regeneron Pharmaceuticals

Testing Dazucorilant against a placebo for amyotrophic lateral sclerosis

Explore this study →

There are 4 groups in this study. Group A receives Dazucorilant 300 mg. Group B receives one or more of: Dazucorilant 150 mg and Placebo. Group C, the placebo group, receives Placebo. …and 1 more groups.

Sites in Hamilton and Montreal

Phase 2
4 groups
Sites in Hamilton and Montreal
Recruiting

Official title: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis · Corcept Therapeutics

Testing Repetitive Transcranial Magnetic for amyotrophic lateral sclerosis

Explore this study →

Everyone in this study is in one group and receives Repetitive Transcranial Magnetic Stimulation.

One site, in Toronto

1 group
One site, in Toronto
Recruiting

Official title: Quantitative and Repetitive TMS in ALS - Recruiting for Stage 2

Amyotrophic Lateral Sclerosis · Sunnybrook Health Sciences Centre

Testing 50 mg Usnoflast against a placebo for amyotrophic lateral sclerosis (ALS)

Explore this study →

There are 3 groups in this study. Group A, the comparison group, receives 50 mg Usnoflast. Group B, the comparison group, receives 75 mg Usnoflast. Group C, the placebo group, receives Placebo.

Sites in Québec and Toronto

Phase 2
3 groups
Sites in Toronto and Québec
Recruiting

Official title: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) · Zydus Therapeutics Inc.

Testing COYA 302 against a placebo for amyotrophic lateral sclerosis (ALS)

Explore this study →

There are 5 groups in this study. Group A receives COYA 302, together with one or more of: Placebo. Groups B, D and E receive COYA 302. Group C, the placebo group, receives Placebo.

Sites in London, Montreal and 2 more cities

Phase 2
5 groups
Sites in Vancouver, London and 2 more cities
Recruiting

Official title: Study of COYA 302 for the Treatment of ALS

Amyotrophic Lateral Sclerosis (ALS) · Coya Therapeutics

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Amyotrophic Lateral Sclerosis trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.